Table 3. Estimated ORs and 95% CIs for the association of frequency and duration of aspirin, non-aspirin NSAIDs, and acetaminophen use with ovarian cancer risk.
|
Aspirin |
Non-aspirin NSAID |
Acetaminophen |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| No. of cases | No. of controls | Adjusted ORa | No. of cases | No. of controls | Adjusted ORa | No. of cases | No. of controls | Adjusted ORa | |
| (n=432) | (n=560) | (95% CI) | (n=474) | (n=628) | (95% CI) | (n=416) | (n=534) | (95% CI) | |
| Never users | 362 | 467 | 1.00 (Referent) | 362 | 467 | 1.00 (Referent) | 362 | 467 | 1.00 (Referent) |
|
Frequency of use | |||||||||
| <30 Days/month | 15 | 27 | 0.51 (0.21–1.25) | 58 | 108 | 0.54 (0.35–0.83) | 35 | 48 | 0.94 (0.49–1.81) |
| Daily | 55 | 66 | 0.56 (0.34–0.94) | 54 | 53 | 1.15 (0.70–1.91) | 19 | 19 | 0.79 (0.33–1.92) |
|
Duration of use | |||||||||
| <5 Years | 27 | 41 | 0.52 (0.28–0.98) | 33 | 51 | 0.81 (0.48–1.37) | 15 | 25 | 0.97 (0.42–2.22) |
| ⩾5 Years | 43 | 52 | 0.60 (0.32–1.11) | 79 | 110 | 0.71 (0.47–1.07) | 39 | 42 | 0.87 (0.44–1.74) |
|
Frequency, duration of use | |||||||||
| <30 Days/month for <5 years | 7 | 13 | 0.43 (0.14–1.34) | 20 | 33 | 0.67 (0.35–1.27) | 8 | 18 | 0.94 (0.34–2.63) |
| Daily for <5 years | 20 | 28 | 0.56 (0.27–1.11) | 13 | 18 | 1.13 (0.48–2.66) | 7 | 7 | 1.12 (0.32–3.96) |
| <30 Days/month for ⩾5 years | 8 | 14 | 0.61 (0.17–2.22) | 38 | 75 | 0.47 (0.28–0.79) | 27 | 30 | 1.00 (0.45–2.21) |
| Daily for ⩾5 years | 35 | 38 | 0.56 (0.29–1.08) | 41 | 35 | 1.17 (0.65–2.09) | 12 | 12 | 0.58 (0.19–1.79) |
Abbreviations: CI=confidence interval; NSAID= nonsteroidal anti-inflammatory drug; OR=odds ratio.
a
Adjusted for age, study site, education, income, parity, family history of first-degree relative with breast or ovarian cancer, tubal ligation, body mass index (BMI), oral contraceptive use, menopausal status, endometriosis, pelvic inflammatory disease, physical activity, and simultaneous adjustment of use of other analgesics (frequency, duration).